Lipid and cholesterol metabolism regulators

Lipid and cholesterol metabolism regulators represent a diverse group of molecular targets, including enzymes, receptors, and transporters, that collectively maintain systemic lipid homeostasis. Key components of this regulatory network include HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, and the Low-Density Lipoprotein Receptor (LDLR), which is responsible for clearing LDL particles from circulation (UniProt, 2024). Other critical regulators include the NPC1L1 transporter for intestinal absorption and the PCSK9 protein, which modulates LDLR degradation (PubMed, 2023). Dysregulation of these pathways is a major contributor to hypercholesterolemia and the development of atherosclerotic cardiovascular disease (ASCVD). Therapeutic strategies targeting these regulators, such as statins, ezetimibe, and PCSK9 inhibitors, are foundational in clinical practice for reducing cardiovascular risk and managing metabolic disorders (StatPearls, 2023). These targets are also involved in broader metabolic processes, including bile acid synthesis and fatty acid oxidation, making them central to the treatment of nonalcoholic fatty liver disease and metabolic syndrome.

Other names

Lipid-lowering targetsCholesterol homeostasis proteinsHypolipidemic agentsDyslipidemia regulators

This category encompasses multiple mechanisms including the inhibition of HMG-CoA reductase to decrease endogenous cholesterol synthesis, inhibition of the NPC1L1 transporter to reduce intestinal cholesterol absorption, and inhibition of PCSK9 to increase LDL receptor density and hepatic clearance of LDL-C (StatPearls, 2023; PubMed, 2022).